MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fped.2026.1808733

Медицинская библиотека · Frontiers in pediatrics · 2026

Real-world effectiveness and safety of dupilumab therapy in children ≤6 years with uncontrolled persistent asthma: a propensity-matched retrospective cohort study.

Mazi Ahlam, Aljohany Azizah, Fouad Michele, Hamadallah Hanaa, Bukhari Esraa M, Bayomi Doaa, Alsulaimani Samahir, Gazzaz Nour, Sharara Muhannad, Dobs Monica

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Asthma is common in children. Dupilumab is a biological agent that showed effectiveness in older children with uncontrolled asthma; however, its efficacy and safety are lacking among the very young children (≤6) who were excluded from clinical trials.

METHODS

Using TriNetX, children ≤6 years old with persistent asthma who received a concomitant prescription for dupilumab for any indication, in addition to standard asthma treatment, were compared with those on standard treatment alone. Using 1:1 propensity score matching across 35 covariates, outcomes such as acute exacerbations, status asthmaticus, need for oral corticosteroid (OCS), emergency room (ER) visits, anaphylaxis, infections, and inpatient admissions were assessed at 6 and 12 months.

RESULTS

Of 44,952 patients analyzed, 301 patients were matched per group. Asthmatic children with concomitant dupilumab prescriptions were associated with a reduction in acute exacerbations at 6 and 12 months (RR 0.53 and 0.46, respectively; p < 0.05), OCS use (RR 0.67 and 0.66; p < 0.05), ER visits, and infections (all p < 0.05). However, the risk of anaphylaxis was higher in cohort one at 6 and 12 months (RR 1.80 and 1.74; p < 0.05). Other outcomes, such as status asthmaticus, eosinophilia, and inpatient admissions, were similar between the cohorts.

CONCLUSIONS

This real-world analysis shows dupilumab therapy alongside standard treatment in children ≤6 years with persistent asthma is significantly associated with reduced acute exacerbations, OCS use, and ER visits. These findings support dupilumab's clinical benefit for this vulnerable group, aiding clinical decisions.

Для цитирования: Mazi Ahlam, Aljohany Azizah, Fouad Michele, Hamadallah Hanaa, Bukhari Esraa M, Bayomi Doaa, Alsulaimani Samahir, Gazzaz Nour, Sharara Muhannad, Dobs Monica. Real-world effectiveness and safety of dupilumab therapy in children ≤6 years with uncontrolled persistent asthma: a propensity-matched retrospective cohort study.. Frontiers in pediatrics. 2026. DOI: 10.3389/fped.2026.1808733.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.